Sinha Chandrima, Cunningham Lea C
Department of Bone Marrow Transplant & Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee.
Pediatr Blood Cancer. 2016 Dec;63(12):2078-2085. doi: 10.1002/pbc.26171. Epub 2016 Aug 18.
Patients with acute myeloid leukemia (AML) have relatively low survival rates compared to patients with other pediatric cancers. Relapse is frequent with conventional treatment and is a major cause of morbidity and mortality. Natural killer (NK) cells offer an alternative approach to chemotherapy that combats relapse by substantially eradicating AML blasts. New methods for enhancing NK cell activation and expression of the activating ligand on target malignant cells will increase the likelihood of success with this approach. We review these latest discoveries in NK cell-based therapy for AML and delineate recent advances in sensitizing AML cells to NK cell-mediated immunosurveillance.
与其他儿童癌症患者相比，急性髓系白血病（AML）患者的生存率相对较低。传统治疗方法经常导致复发，是发病和死亡的主要原因。自然杀伤（NK）细胞为化疗提供了一种替代方法，通过大量清除AML母细胞来对抗复发。增强NK细胞活化以及靶恶性细胞上活化配体表达的新方法将增加这种方法成功的可能性。我们综述了基于NK细胞治疗AML的这些最新发现，并阐述了使AML细胞对NK细胞介导的免疫监视敏感化的最新进展。
